PMID: 9544380Apr 17, 1998Paper

Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance

Australian and New Zealand Journal of Medicine
G M ForbesP D Robins

Abstract

Limited Australian data are available on either short duration therapy for Helicobacter pylori infection, or the impact of metronidazole resistance on the outcome of treatment. To compare the efficacy of two treatment regimens and determine the influence metronidazole resistance has on clearing H. pylori infection. Eighty patients with H. pylori infection proven at upper gastrointestinal endoscopy, none of whom had previously received therapy for H. pylori, were randomised to one week therapy with either bismuth subcitrate one tablet qid, tetracycline 500 mg qid and metronidazole 400 mg tds (BTM), or lansoprazole 30 mg bd, amoxycillin 500 mg qid and metronidazole 400 mg tds (LAM). Effectiveness of therapy was measured by C14-urea breath test at six weeks. On an intention-to-treat basis, clearance of infection was achieved in 17 of 32 (53%; 95% CI: 35-71%) evaluable patients receiving BTM and 32 of 46 (70%, 54-82%) patients receiving LAM (p = 0.16). Metronidazole resistance was found in 32 of 65 (49%) patients in whom H. pylori was isolated by culture. On a per-protocol basis, of patients who had metronidazole sensitive strains of H. pylori 23 of 24 (96%) cleared infection after therapy with either BTM or LAM, compared with 14 o...Continue Reading

Citations

Jun 27, 2000·Australian and New Zealand Journal of Medicine·A G FraserB Hollis
May 26, 2001·The American Journal of Gastroenterology·D J Kearney
Jun 26, 1999·Alimentary Pharmacology & Therapeutics·M OkadaT Takata
Jun 6, 2002·Helicobacter·Robert A LockGeoffrey M Forbes
Jan 10, 2003·Journal of Gastroenterology and Hepatology·Reza MalekzadehAli Majidpour
Jul 31, 2003·Journal of Paediatrics and Child Health·S RerksuppapholP Ward
Nov 21, 2020·Journal of Gastroenterology and Hepatology·Jonathon P SchubertRobert V Bryant
Feb 24, 2001·The Medical Journal of Australia·L C MollisonD B McGechie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.